{"title":"Three experts resign as FDA advisers over approval of Alzheimer’s drug","link":"https://arstechnica.com/?p=1772629","date":1623449220000,"content":"<div>\n<figure><img src=\"https://cdn.arstechnica.net/wp-content/uploads/2019/05/GettyImages-496532228-800x512.jpg\" /><p><a href=\"https://cdn.arstechnica.net/wp-content/uploads/2019/05/GettyImages-496532228.jpg\">Enlarge</a> <span>/</span> The Food and Drug Administration headquarters in White Oak, Maryland. (credit: <a href=\"https://www.gettyimages.com/detail/news-photo/the-outside-of-the-food-and-drug-administration-news-photo/496532228?adppopup=true\">Getty | Congressional Quarterly</a>)</p>  </figure><div><a name=\"page-1\"></a></div>\n<p>Fallout continues from the Food and Drug Administration’s <a href=\"https://arstechnica.com/science/2021/06/a-disgraceful-decision-researchers-blast-fda-for-approving-alzheimers-drug/\">contentious decision</a> this week to approve Biogen’s Alzheimer’s drug Aduhelm (aducanumab) despite a lack of efficacy data.</p>\n<p>Three experts who sat on an advisory committee for the FDA have now resigned over the decision.</p>\n<p>The advisory committee reviewed the data behind Aduhelm last November and voted overwhelmingly against approval. Of the 11 advisers on the committee, <a href=\"https://www.fda.gov/media/145691/download\">10 voted “no”</a> on the question of whether Biogen had collected enough evidence to indicate that the drug is effective. The remaining adviser voted “uncertain.”</p></div><p><a href=\"https://arstechnica.com/?p=1772629#p3\">Read 9 remaining paragraphs</a> | <a href=\"https://arstechnica.com/?p=1772629&amp;comments=1\">Comments</a></p>","author":"Beth Mole","siteTitle":"Ars Technica","siteHash":"5b0ddf6e8923e49262a7894cfd77962733e43fbcc565a103b48373820b310636","entryHash":"e81151a705d4ec57e8ca7f932ee91dd9a7cace6329924506088fa20210f5b29a","category":"Tech"}